R&D Sponsored Advancing RSV and hMPV research through human challenge tria... Human challenge trials offer a complementary approach, and hVIVO has been at the forefront of this field for decades.
Patients The ins and outs of HEOR – A lever for global health Web editor Nicole Raleigh speaks with Rob Abbott, CEO and executive director of ISPOR, about the ins and outs and trends of HEOR.
Patients Op-ed: Pharma must show courage, leadership on public health Pharma companies can't claim to care about global patient wellbeing unless they stand up to Trump's public health cuts.
Digital Retaining the human element in healthcare services whilst em... In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Gavin Anderson, a man of many hats all orbiting around technology and business.
Patients The paradox of cardiovascular disease: Out in the open, but ... When prompted with the question, ’What is the world’s deadliest disease?’, what would be your first guess?
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.